Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Total Debt (2016 - 2021)

GT Biopharma (GTBP) has disclosed Total Debt for 12 consecutive years, with $371000.0 as the latest value for Q3 2021.

  • On a quarterly basis, Total Debt fell 98.39% to $371000.0 in Q3 2021 year-over-year; TTM through Sep 2021 was $371000.0, a 98.39% decrease, with the full-year FY2020 number at $415000.0, down 96.87% from a year prior.
  • Total Debt was $371000.0 for Q3 2021 at GT Biopharma, down from $873000.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $23.0 million in Q3 2020 to a low of $31000.0 in Q3 2017.
  • A 5-year average of $7.4 million and a median of $4.9 million in 2018 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: skyrocketed 34183.87% in 2018, then plummeted 98.39% in 2021.
  • GT Biopharma's Total Debt stood at $31000.0 in 2017, then surged by 34183.87% to $10.6 million in 2018, then rose by 24.56% to $13.2 million in 2019, then plummeted by 96.87% to $415000.0 in 2020, then fell by 10.6% to $371000.0 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Total Debt are $371000.0 (Q3 2021), $873000.0 (Q2 2021), and $393000.0 (Q1 2021).